Eli Lilly and Company (NYSE: LLY) is one of the 10 Best AI Stocks to Buy According to Goldman Sachs. On September 18, Wells Fargo reiterated a Buy rating on Eli Lilly and Company (NYSE:LLY) stock, maintaining the price target at $1,100.

HOUSTON — Eli Lilly and Co. (NYSE: LLY) has unveiled plans to build a new $6.5 billion manufacturing facility at Generation Park, a 4,000-acre master-planned development in northeast Houston that is owned by McCord Development.

Eli Lilly plans to build a $6.5 billion factory in Houston, with construction expected to be completed by 2030.

PGIM, an investment management company, released its “PGIM Jennison Health Sciences Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equities in the second quarter of 2025 experienced significant volatility,

Eli Lilly said on Thursday the U.S. Food and Drug Administration has approved its treatment for a form of advanced breast cancer in adult patients who have received prior therapy. The therapy, Inluriyo,

To avoid tariffs and boost production, Celltrion will pay $330 million to acquire a Branchburg manufacturing facility of Eli Lilly.

Even though Eli Lilly and Company (NYSE:LLY)’s shares have lost 6.9% year-to-date, Cramer continues to be a believer in the stock.

Eli Lilly (LLY) remains a strong growth company, driven by leadership in the booming GLP-1 and diabetes drug markets despite recent share price weakness. LLY's aggressive investments in manufacturing, superior clinical trial results, and AI-driven drug discovery reinforce its competitive edge and future revenue potential.

Eli Lilly's GLP-1 Pill Just Beat Out Novo Nordisk's in a Test. Here's 1 Thing Investors Need to Know. The secondary endpoints included weight loss, and, here again, orforglipron demonstrated superiority in the trial, according to the company.

Eli Lilly will invest $6.5 billion to build a state-of-the-art biomanufacturing facility in Houston, creating 600 jobs and boosting production of advanced therapies.

Eli Lilly will make its next-generation experimental weight-loss pill, orforglipron, at a new multi-billion-dollar manufacturing plant it plans to build in Texas, the company said on Tuesday. Lilly said it would invest $6.